Skip to content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
Get the latest shareable resources on coping with COVID-19 from NIMH: https://www.nimh.nih.gov/covid19

Novel Pharmacologic and Device-based Intervention Program for Pediatrics

Overview

This program supports research leading to the development of novel pharmacologic and device-based treatments for childhood-onset mental disorders. Of interest is research to evaluate the molecular and circuit-base targets of these interventions, to optimize dosing, to evaluate safety and tolerance, and to evaluate the association between target engagement and the effect on symptoms or functional domains. Also of interest are the development of reliable and stable biomarkers of pediatric approved drug and device-based interventions to provide missing information highly needed in the field on the central targets and mechanisms; indicators of treatment response or drug safety; and to biologically identify subjects that would best respond to the intervention for stratification purposes.

Related Funding Opportunity Announcements

The following funding opportunity announcements may be of interest for researchers studying the development of novel pharmacologic treatments for pediatric mental disorders. Learn more about additional NIH and NIMH funding opportunities.

Contact

Margaret C. Grabb, Ph.D.
Program Chief
6001 Executive Boulevard, Room 7203, MSC 9645
301-443-3563, mgrabb@mail.nih.gov